Glycans in cancer and inflammation — potential for therapeutics and diagnostics

By Danielle H. Dube, Carolyn R. Bertozzi. Nature reviews. Drug discovery, 2005

1,514 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

From antimicrobial to anticancer peptides. A review (2013, background): “In addition to the modified glycosilation profile typical of cancer tissues and which is directly associated with the tumor phenotype (Dube and Bertozzi, 2005), during cell transformation PS molecules will present themselves on the outer membrane leaflet, accumulating on site and counteracting the…”
Protein Glycosylation in Cancer (2015, background): “Incorporation of antineoplastic agents into these probes could offer another strategy to specifically target neoplastic lesions that may preferentially incorporate a particular carbohydrate analog (59, 224).”
Turning 'sweet' on immunity: galectin–glycan interactions in immune tolerance and inflammation (2009, background): “Recent advances have enabled the association of specific glycosylation signatures with particular disease states, including cancer and metastasi”
The sweet and sour of cancer: glycans as novel therapeutic targets (2005, background): “have been extensively reviewed elsewhere [9, 19].”